MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Consolidation of learning and memory in Parkinson’s disease

    M.E. Sharp, K. Duncan, K. Foerde, R. Kahane, D. Shohamy (New York City, NY, USA)

    Objective: To determine if Parkinson's disease causes an impairment in the ability to consolidate learning into long-term memory and to determine if this deficit is…
  • 2016 International Congress

    Treatment with the use of the PD-specific scales for patients suffering from subcortical Parkinsonian dementia

    N.G. Sokhibnazarov, F.K. Shermukhamedova (Tashkent, Uzbekistan)

    Objective: Aim of this study was to identify the degree of cognitive dysfunction in patients with subcortical Parkinsonian dementia, during the neuroprotective therapy. Background: Parkinson's…
  • 2016 International Congress

    Cognitive complaint in Parkinson’s disease patients with normal cognition

    R.F. Purri, L. Brennan, J. Rick, L. Chahine, N. Dahodwala, A. Chen-Plotkin, J.E. Duda, J.F. Morley, R.S. Akhtar, J.Q. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

    Objective: To characterize cognitively normal PD patients who endorse cognitive complaint, and to assess their cognitive performance over time. Background: PD patients are at a…
  • 2016 International Congress

    Impaired cube copy on the MOCA indicates worse performance in several cognitive domains in Parkinson´s disease

    C. Gasca-Salas, M. Cohn, J.A. Pineda, J.A. Obeso (Madrid, Spain)

    Objective: We aimed to identify if an impairment of the cube copy of the Montreal Cognitive assessment (MoCA) was associated with worse cognitive status in…
  • 2016 International Congress

    Construct validity of Moca test in a sample of patients with Parkinson´s disease in Bogotá and Cali – Colombia

    B.E. Muñoz, O. Bernal, A. Castillo, J.L. Orozco (Cali, Colombia)

    Objective: To evaluate of construct validity for a sample of patients with PD in Bogotá and Cali - Colombia. Background: Parkinson´s disease (PD) is a…
  • 2016 International Congress

    The alterations in behavioral memory for prolongation disease duration in patients with Parkinson’s disease

    M. Saruwatari, Y. Kobayashi, A. Kumon, K. Hasegawa (Sagamihara, Japan)

    Objective: Aim of this study is to assess the alterations in daily behavioral memory for prolongation of disease duration in PD. Background: We are continuing…
  • 2016 International Congress

    Apraxia in Parkinson’s disease

    M. Tábuas-Pereira, P. Correia, F. Moreira, A. Morgadinho, C. Januário (Coimbra, Portugal)

    Objective: We aim to study apraxia in Parkinson's disease. Background: Limb apraxia is a cognitive motor disorder of skilled, purposive movements not caused by elementary…
  • 2016 International Congress

    Imitation of hand movements in Parkinson’s disease: A comparison with visual cueing

    J. Bek, E. Gowen, S. Vogt, T. Crawford, E. Stack, J. Dick, E. Poliakoff (Manchester, United Kingdom)

    Objective: To explore imitation and its therapeutic potential in Parkinson's disease (PD) using kinematic analysis of hand movements. Background: Action observation and imitation have been…
  • 2016 International Congress

    The cognitive profile of idiopathic REM sleep behavior disorder

    L. Bernier-Lalonger, F. Escudier, P.A. Bourgouin, R.B. Postuma, J. Montplaisir, J.F. Gagnon (Montreal, QC, Canada)

    Objective: The aim of this study was to examine the cognitive profile in a large cohort of patients with idiopathic REM sleep behavior disorder (iRBD).…
  • 2016 International Congress

    Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension

    K.E. McDonell, C.A. Shibao, I. Biagginoi, D. Robertson, D.O. Claassen (Nashville, TN, USA)

    Objective: To describe adverse behavioral symptoms attributed to droxidopa therapy for neurogenic orthostatic hypotension (nOH). Background: Droxidopa, a norepinephrine (NE) precursor, improves symptoms of neurogenic…
  • « Previous Page
  • 1
  • …
  • 1488
  • 1489
  • 1490
  • 1491
  • 1492
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • #25179 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley